Microbicide Effects on Efficacy, Safety, Innate Immunity
Microbicide Effects on Efficacy, Safety, Innate Immunity
批准号:
7572920
负责人:
MARLA J KELLER
金额:
$44.23万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-09-01 至 2012-02-29
关键词:
AccountingAcidsAdvanced DevelopmentAlkanesulfonatesAntiviral AgentsAttentionBindingBiological AssayBiological Response ModifiersBuffersCD4 Positive T LymphocytesCell CommunicationCell Culture SystemCellsCervicalClinical TrialsComplexCyclin-Dependent KinasesDataDefensinsDendritic CellsDevelopmentDrug FormulationsEnvironmentEvaluationHIVHIV InfectionsHIV-1HeterosexualsHost DefenseImmune responseIn VitroInfectionLaboratoriesLiquid substanceLocal MicrobicidesMediatingMediator of activation proteinMolecularMucous MembraneNatural ImmunityOutcomePharmaceutical ChemistryPharmaceutical PreparationsPilot ProjectsPlayPolymersPredictive ValuePreventionProtocols documentationQuinonesRelative (related person)RiskRoleRouteSAMMASafetySimplexvirusSimulateSurrogate MarkersT-LymphocyteTenofovirTherapeuticTimeVaccinesVaginaViralVirusWomanWorkantileukoproteasecellular targetingcellulose sulfatecytokinedesigninhibitor/antagonistmacrophagemenmicrobicidenovelprogramsresearch clinical testingtransmission processvaginal fluid
中文摘要
异性传播艾滋病毒是女性的主要途径,目前女性占感染者的50%。
在缺乏有效疫苗的情况下,需要其他预防模式。一种安全有效的专题报道
杀微生物剂将使女性和男性在保护自己方面发挥更直接的作用。就像治疗性的
HIV的方法,一种将具有不同作用模式的化合物结合在一起的局部杀微生物剂
在阻断传播时在粘膜中发生的复杂相互作用方面的优势。
许多将使用这种化合物的有风险的女性将不知道自己的艾滋病毒状况。因此,一种杀微生物剂
方法必须考虑受感染妇女接触化合物的影响,因此必须考虑局部药物的影响
不代表主要的治疗抗逆转录病毒药物可能是一个优势。鉴于有证据表明单纯疱疹病毒
增强艾滋病毒传播,对其他性传播感染也有影响的药物将有额外的好处。这种方法
必须是安全的,不能干扰感染的自然屏障。推进科技进步的途径
本计划中提出的候选杀微生物剂考虑了这些问题中的每一个。我们正在提议
推动新型化合物SAMMA向含有酸的配方产品的发展
将SAMMA的进入抑制活性与酸性pH对病毒的直接影响结合在一起的缓冲液。
我们还将探索其他化合物的潜力,如新型过硫酸盐分子伞(PMU)。
以及CDK抑制剂。这两类化合物都具有抗HIV和HSV的活性。这其中的每一个
将仔细研究各种方法,重点不仅是推进候选化合物,而且是拓宽
我们对关键宿主防御和局部杀菌剂之间相互作用的理解。小心地
已在临床试验中的化合物的计划中试临床评估(硫酸纤维素、酸仿和
替诺福韦)以及拟议的配方SAMMA将重点放在这些化合物对
先天免疫以及疗效替代标记物的开发。
英文摘要
Heterosexual transmission of HIV is the primary route in women, who now account for 50% of those infected.
In the absence of an effective vaccine, other modes of prevention are needed. A safe and effective topical
microbicide will allow women and men to play a more direct role in their own protection. As with therapeutic
approaches to HIV, a topical microbicide that combines compounds with differing modes of action will have
an advantage in blocking the complex interactions that occur in the mucosa at the time of transmission.
Many women at risk who will use the compounds will not know their HIV status. Therefore, a microbicide
approach must consider the impact of exposure of infected women to the compound and therefore topicals
that do not represent major therapeutic antiretrovirals might be an advantage. Given the evidence that HSV
enhances HIV transmission, agents that also impact on other STI will have an added benefit. This approach
must be safe and not interfere with natural barriers to infection. The approach to the advancement of
candidate microbicides proposed in this program takes into account each of these issues. We are proposing
to advance the development of the novel compound SAMMA to formulated product that will include an acid
buffer to combine the entry inhibitory activity of SAMMA with the direct effects of an acid pH on the virus.
We will also explore the potential of other compounds such as novel persulfated molecular umbrellas (pmu)
as well as cdk inhibitors. Both classes of compounds have activity against HIV and HSV. Each of these
approaches will be carefully studied focusing not only on advancing candidate compounds but broadening
our understanding of the interaction between critical host defenses and topical microbicides. Carefully
planned pilot clinical evaluation of compounds already in clinical trials (cellulose sulfate, acidform and
tenofovir) as well as the proposed formulated SAMMA will focus on the effects of these compounds on
innate immunity as well as the development of surrogate markers for efficacy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Einstein-Montefiore Clinical and Translational Science Award Hub
-
批准号:10622099
-
项目类别:
-
资助金额:$436.8万
-
财政年份:2023
-
负责人:MARLA J KELLER
-
依托单位:
Convalescent Plasma to Limit Coronavirus Associated Complications: A Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-SARS-CoV-2 Plasma to Placebo in COVID-19 hospitalized pa
-
批准号:10166008
-
项目类别:
-
资助金额:$432.52万
-
财政年份:2020
-
负责人:MARLA J KELLER
-
依托单位:
CTSA Administrative Supplement for Informatics Core: A novel AI/ML system to predict respiratory failure and ARDS in Covid-19 patients
-
批准号:10158737
-
项目类别:
-
资助金额:$100.34万
-
财政年份:2020
-
负责人:MARLA J KELLER
-
依托单位:
Clinical and Translational Science Award
-
批准号:10112978
-
项目类别:
-
资助金额:$427.42万
-
财政年份:2018
-
负责人:MARLA J KELLER
-
依托单位:
Clinical and Translational Science Award
-
批准号:9886296
-
项目类别:
-
资助金额:$427.42万
-
财政年份:2018
-
负责人:MARLA J KELLER
-
依托单位:
Clinical and Translational Science Award
-
批准号:10357784
-
项目类别:
-
资助金额:$427.42万
-
财政年份:2018
-
负责人:MARLA J KELLER
-
依托单位:
Modifies of PrEP Efficacy in US & African Women: Age, Hormones, Sex & Microbiota
-
批准号:8448509
-
项目类别:
-
资助金额:$89.57万
-
财政年份:2013
-
负责人:MARLA J KELLER
-
依托单位:
Safety of Non-Medicated Intravaginal Rings for Microbicide Delivery
-
批准号:8012508
-
项目类别:
-
资助金额:$12.45万
-
财政年份:2010
-
负责人:MARLA J KELLER
-
依托单位:
Clinical Study to Measure Pharmacokinetics, Pharmacodynamics and Safety of a TDF
-
批准号:8210597
-
项目类别:
-
资助金额:$46.11万
-
财政年份:2009
-
负责人:MARLA J KELLER
-
依托单位:
EFFECTS OF HORMONES ON MUCOSAL IMMUNE MEDIATORS ACROSS THE MENSTRUAL CYCLE
-
批准号:7718170
-
项目类别:
-
资助金额:$17.93万
-
财政年份:2008
-
负责人:MARLA J KELLER
-
依托单位:
EFFECTS OF HORMONES ON MUCOSAL IMMUNE MEDIATORS ACROSS THE MENSTRUAL CYCLE
-
批准号:7605356
-
项目类别:
-
资助金额:$3.4万
-
财政年份:2007
-
负责人:MARLA J KELLER
-
依托单位:
THE EFFICACY OF SAMMA AND ITS LEADING DERIVATIVES AGAINST HIV-1
-
批准号:7605277
-
项目类别:
-
资助金额:$4.1万
-
财政年份:2007
-
负责人:MARLA J KELLER
-
依托单位:
EFFECTS OF HIV ON BONE MASS IN THE ELDERLY
-
批准号:7380524
-
项目类别:
-
资助金额:$4.59万
-
财政年份:2006
-
负责人:MARLA J KELLER
-
依托单位:
EFFECT OF REPEATED APPLICATIONS OF PRO 2000/5 GEL (P) ON INFLAMMATORY MEDIATORS
-
批准号:7380538
-
项目类别:
-
资助金额:$2.69万
-
财政年份:2006
-
负责人:MARLA J KELLER
-
依托单位:
MULTITARGETED MICROBICIDE COMBINATIONS TO BLOCK HIV
-
批准号:7380518
-
项目类别:
-
资助金额:$5.38万
-
财政年份:2006
-
负责人:MARLA J KELLER
-
依托单位:
TO EVALUATE THE EFFICACY OF SAMMA AND ITS LEADING DERIVATIVES AGAINST HIV-1
-
批准号:7380526
-
项目类别:
-
资助金额:$4.9万
-
财政年份:2006
-
负责人:MARLA J KELLER
-
依托单位:
Microbicide Effects on Efficacy, Safety, Innate Immunity
-
批准号:7531462
-
项目类别:
-
资助金额:$20.01万
-
财政年份:2005
-
负责人:MARLA J KELLER
-
依托单位:
Microbicide Effects on Efficacy, Safety, Innate Immunity
-
批准号:7221949
-
项目类别:
-
资助金额:$20.74万
-
财政年份:2005
-
负责人:MARLA J KELLER
-
依托单位:
EFFECT OF REPEATED APPLICATIONS OF PRO 2000/5 GEL (P) ON INFLAMMATORY MEDIATO
-
批准号:7202511
-
项目类别:
-
资助金额:$11.22万
-
财政年份:2005
-
负责人:MARLA J KELLER
-
依托单位:
MULTITARGETED MICROBICIDE COMBINATIONS TO BLOCK HIV
-
批准号:7202486
-
项目类别:
-
资助金额:$7.16万
-
财政年份:2005
-
负责人:MARLA J KELLER
-
依托单位:
国内基金
海外基金
登录
查看更多内容
抗禾谷镰刀菌3-Decalinoyltetramic Acids类天然产物的挖掘及基于“靶标垂钓”策略的作用机制研究
-
批准号:32470420
-
项目类别:面上项目
-
资助金额:50.00万元
-
批准年份:2024
-
负责人:赵栋霖
-
依托单位:
真菌中同一PKS-NRPS基因簇合成两种不同骨架tetramic acids机制研究
-
批准号:32470051
-
项目类别:面上项目
-
资助金额:50.00万元
-
批准年份:2024
-
负责人:张伟
-
依托单位:
具有抗癌活性的天然产物金霉酸(Aureolic acids)全合成与选择性构建2-脱氧糖苷键
-
批准号:22007039
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:王黎明
-
依托单位:
海洋放线菌来源聚酮类化合物Pteridic acids生物合成机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2019
-
负责人:朱义广
-
依托单位:
手性Lewis Acids催化的分子内串联1,5-氢迁移/环合反应及其在构建结构多样性手性含氮杂环化合物中的应用
-
批准号:21372217
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:袁伟成
-
依托单位:
对空气稳定的新型的有机金属Lewis Acids催化剂制备、表征与应用研究
-
批准号:21172061
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2011
-
负责人:许新华
-
依托单位:
钛及含钛Lewis acids促臭氧/过氧化氢体系氧化性能的广普性、高效性及其机制
-
批准号:21176225
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2011
-
负责人:童少平
-
依托单位:
基于Zip Nucleic Acids引物对高度降解和低拷贝DNA检材的STR分型研究
-
批准号:81072511
-
项目类别:面上项目
-
资助金额:31.0万元
-
批准年份:2010
-
负责人:严江伟
-
依托单位:
海洋天然产物Makaluvic acids 的全合成及其对南海鱼虱存活的影响
-
批准号:30660215
-
项目类别:地区科学基金项目
-
资助金额:21.0万元
-
批准年份:2006
-
负责人:王世范
-
依托单位: